Skip Ribbon Commands Skip to main content
:

profile


Profile Image

Xiaoqi Liu

Biochemistry 

  • Professor Biochem/Cancer Rsr
  • Associate Professor of Biochem/Cancer Rsr
765.496.3764
765.494.7897
BIND Room 290

Lab Members


Area of Expertise: Roles of Polo-like kinase 1 and its interacting proteins in cell proliferation and carcinogenesis

Current therapeutic strategies for cancer patients have shown only moderate success in reducing incidence and mortality rates and improving survival, thus a new class of more specific treatments for various cancers is greatly needed. A major goal in cancer research is to understand the molecular events that are associated with this disease to aid in the development of such novel therapies. The long-term goal of my research program is to understand the molecular mechanisms that cause cancer and to use this information to provide new avenues for cancer therapy. My work focuses on an enzyme known as Polo-like kinase 1 (Plk1), which plays a central role in controlling cell division and is known to exist at abnormally high levels in many types of human cancers. Compounds that inhibit Plk1 are currently viewed as promising new anti-cancer drugs. To fully exploit Plk1 as a potential anticancer drug target, it is essential to fully understand its regulation and function, particularly in the context of the cancer cell. We have made a series of contributions to understanding both Plk1 regulation and its function and the lab is in a position to make crucial contributions in understanding how Plk1 can be exploited as a target for drugs to treat cancer and other important human diseases. The lab is currently using a combination of biochemistry, cell biology and mouse genetics to dissect the roles of Plk1 in initiation, progression and metastasis of prostate and pancreatic cancer.

Awards & Honors

(2004) Don Wiley Award provided. Merck.

(2005) Howard Temin Award. NIH.

(2011) Richard L. Kohls Outstanding Early Career Award for Excellent Undergraduate teaching. Purdue University.

(2013) The American Cancer Society Research Scholar. The American Cancer Society.

(2014) Richard L. Kohls Outstanding Early Career Award for Excellent Undergraduate teaching. Purdue University.

(2012) Seed for Success Award. Purdue University.

Selected Publications

Shao, T., & Liu, X. (2015). Identification of Rictor as a Novel Substrate of Polo-like kinase 1. Cell Cycle, 14, 755-760.

Song, B., Liu, X., Rice, S., Kuang, S., Elzey, B., Konieczny, S., Ratliff, T., . . . Liu, X. (2013). Plk1 phosphorylation of Orc2 and Hbo1 contributes to gemcitabine resistance in pancreatic cancer. Mol. Cancer Ther, 12, 58-68. Retrieved from http://mct.aacrjournals.org/content/12/1/58.long

Zhang, Z., Chen, L., Wang, H., Ahmad, N., & Liu, X. (2015). Inhibition of Plk1 represses androgen signaling pathway in castration-resistant prostate cancer. Cell Cycle, 14, 2142-2148.

Hou, X., Zhiguo, L., Huang, W., Li, J., Staiger, C., Kuang, S., Ratliff, T., . . . Liu, X. (2013). Plk1-dependent microtubule dynamics promotes androgen receptor signaling in prostate cancer. The Prostate, 73, 1352-1363. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/pros.22683/abstract;jsessionid=D4E8C8B48AE9E811EAB8EFC7BF227514.d03t01

Shao, C., Ahmad, N., Hodges, K., Kuang, S., Ratliff, T., & Liu, X. (2015). Inhibition of Polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer. J. Biol. Chem, 290, 2024-2033. Retrieved from http://www.jbc.org/content/290/4/2024.full.pdf+html

Li, Z., Li, J., Bi, P., Lu, Y., Burcham, G., Elzey, B., Ratliff, T., . . . Liu, X. (2014). Plk1 phosphorylation of PTEN causes a tumor-promoting metabolic state. Mol. Cell Biol, 34(19), 3642-3661. Retrieved from http://mcb.asm.org/content/34/19/3642.full.pdf+html

Li, Z., Lu, Y., Ahmad, N., Strebhardt, K., & Liu, X. (2015). Low-dose arsenic-mediated metabolic shift is associated with activation of Polo-like kinase 1 (Plk1) Cell Cycle, 14, 3030-3039.

Zhang, Z., Hou, X., Shao, C., Li, J., Cheng, J., Kuang, S., Ahmad, N., . . . Liu, X. (2014). Pik1 inhibition enhances the efficacy of androgen signaling blockade in castration-resistant prostate cancer. Cancer Res, 74, 6635-6647. Retrieved from http://cancerres.aacrjournals.org/content/74/22/6635.full.pdf+html

Chen, L., Li, Z., Ahmad, N., & Liu, X. (2015). Plk1 phosphorylation of IRS2 prevents premature mitotic exit via AKT inactivation. Biochemistry, 54, 2473-2480.

Liu, X., Singh, C. K., & Ahmad, N. (2015). Resveratrol, in its natural combination in whole grape, for health and disease management. Ann. N. Y. Acad. Sci, 1348, 150-160.